Cell line · CVCL_3755
Papers21
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 21
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Triple-Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells' Function and Facilitate Cancer Metastasis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A high-throughput modular microfluidic platform for versatile functional assays at single-cell level. | Microsyst Nanoeng | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Deficient extravillous trophoblast invasion caused by impaired sialylation-Siglec-7 interaction contributes to recurrent pregnancy loss. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma. | Pharmaceuticals (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Colorectal cancer stem cells develop NK cell resistance via homotypic cell-in-cell structures suppressed by Stathmin1. | Theranostics | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Potentiating anti-tumor immunity by re-engaging immune synapse molecules. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure. | J Transl Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. | Sci Immunol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Na+/H+-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. | Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC. | Cancer Cell Int | 2021 | Its Methods give the RRID and name the line | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed | |
| Interleukin-secreting natural killer cell lines and methods of use. | 2011 | Cellosaurus cites it | Cellosaurus |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3755/papers